Suzanne Bruhn, PhD

Dr. Bruhn has served as a director of the Company since August 2022. She is the Chief Executive Officer of the Charcot-Marie-Tooth Association (CMTA), a patient advocacy organization focused on developing treatments for CMT, an inherited progressive peripheral neuropathy, a role she has held since November 2023. Prior to that she was the President and Chief Executive Officer of Tiaki Therapeutics from May 2019 through November 2023 and served as President and Chief Executive Officer of Proclara Biosciences, Inc. from April 2017 until September 2018. Prior to that, Dr. Bruhn served as President and Chief Executive of Promedior, Inc. from 2012 until 2015. Dr. Bruhn previously held numerous senior leadership roles at Shire Human Genetic Therapies, Inc. (a part of Shire Plc.) including as Senior Vice President of Global Regulatory Affairs. Dr. Bruhn has served on the boards of directors of Travere Therapeutics, Inc. since April 2020; and Pliant Therapeutics, Inc. since 2016. Dr. Bruhn previously served on the boards of directors of Vigil Neuroscience from July 2022 until it was acquired by Sanofi in August 2025; Avalo Therapeutics, Inc. (fka Cerecor Inc.) from April 2020 to December 2021; Aeglea BioTherapeutics, Inc. from 2017 through August 2020; Novelion Therapeutics, Inc.; and Raptor Pharmaceuticals Corp. from 2011 until it was acquired by Horizon Pharma plc in 2016.

Dr. Bruhn holds a Bachelor of Science in Chemistry from Iowa State University, a Doctor of Philosophy in Chemistry from the Massachusetts Institute of Technology and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School.